4 h after injection | 24 h after injection | |||||
---|---|---|---|---|---|---|
Blood or tissue | 125I-PIB-ZEGFR:1907 | 125I-PIB-ZTaq | 125I-PIB-(ZEGFR:1907)2 | 125I-PIB-(ZAβ)2 | 125I-PIB-ZEGFR:1907 | 125I-PIB-(ZEGFR:1907)2 |
Blood | 1.2 ± 0.3* | 0.25 ± 0.02 | 1.1 ± 0.5 | 0.052 ± 0.003 | 0.04 ± 0.01* | 0.04 ± 0.01† |
Lung | 0.9 ± 0.2* | 0.12 ± 0.03 | 1.0 ± 0.2† | 0.04 ± 0.01 | 0.05 ± 0.02* | 0.05 ± 0.02† |
Liver | 2.1 ± 0.7*‡ | 0.21 ± 0.03 | 6 ± 2† | 0.05 ± 0.01 | 0.06 ± 0.01*‡ | 0.3 ± 0.2† |
Spleen | 0.31 ± 0.08* | 0.11 ± 0.02 | 0.4 ± 0.2† | 0.065 ± 0.002 | 0.05 ± 0.02* | 0.04 ± 0.02† |
Colon | 0.47 ± 0.10*‡ | 0.10 ± 0.07 | 0.73 ± 0.10 | 0.05 ± 0.02 | 0.02 ± 0.01* | 0.09 ± 0.10† |
Kidney | 6.3 ± 0.6*‡ | 7 ± 2§ | 10 ± 2† | 6 ± 2 | NM | 0.6 ± 0.2† |
Tumor | 2.48 ± 0.10*‡ | 0.2 ± 0.1 | 1.9 ± 0.4 | 0.07 ± 0.05 | 0.26 ± 0.07*‡ | 0.46 ± 0.09† |
Muscle | 0.16 ± 0.06* | 0.03 ± 0.01 | 0.17 ± 0.03 | 0.02 ± 0.01 | 0.02 ± 0.01* | 0.02 ± 0.02† |
Bone | 0.34 ± 0.10 | 0.09 ± 0.03 | 0.32 ± 0.02 | NM | 0.14 ± 0.10 | NM |
Brain | 0.04 ± 0.0* | 0.02 ± 0.02§ | 0.05 ± 0.01 | 0.01 ± 0.01 | 0.01 ± 0.0‡ | 0.010 ± 0.003 |
GI tract‖ | 1.8 ± 0.5* | 0.8 ± 0.4 | 2.5 ± 0.2† | 0.5 ± 0.2 | 0.07 ± 0.01*‡ | 0.18 ± 0.09† |
Carcass‖ | 7 ± 1* | 1.15 ± 0.09 | 8 ± 1† | 0.7 ± 0.2 | 0.6 ± 0.1 | 1.4 ± 0.2† |
↵* Significant difference (P < 0.05, paired t test) between 111In-Bz-DTPA-ZEGFR:1907 and 125I-PIB-ZEGFR:1907.
↵† Significant difference (P < 0.05, unpaired t test) between 111In-Bz-DTPA-(ZEGFR:1907)2 and 125I-PIB-(ZEGFR:1907)2.
↵‡ Significant difference (P < 0.05, unpaired t test) between 125I-PIB-DTPA-ZEGFR:1907 and 125I-PIB-(ZEGFR:1907)2.
↵§ No significant difference (P > 0.05, unpaired t test) between125I-PIB-ZEGFR:1907 and 125I-PIB-ZTaq.
↵‖ Data for gastrointestinal (GI) tract and carcass are presented as % IA per sample.
NM = nonmeasurable.
Data are presented as average %IA/g and SD (n = 4). Nonspecific Affibody molecules ZTaq and (ZAβ)2 have been included as negative control for 125I-PIB-ZEGFR:1907 and 125I-PIB-(ZEGFR:1907)2, respectively.